TY - JOUR
T1 - Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER)
T2 - A Randomized Controlled Trial (SUPER)
AU - Skougaard, Kristin
AU - Østrup, Olga
AU - Guldbrandsen, Kasper Foged
AU - Sørensen, Boe
AU - Meldgaard, Peter
AU - Saghir, Zaigham
AU - Gørtz, Peter Michael
AU - Lonsdale, Markus Nowak
AU - Frank, Malene Støchkel
AU - Gerke, Oke
AU - Rychwicka-Kielek, Beata Agnieszka
AU - Persson, Gitte F.
AU - Land, Lotte Holm
AU - Schytte, Tine Kjestrup
AU - Bodtger, Uffe
AU - Skuladottir, Halla
AU - Søgaard, Jes
AU - Nielsen, Søren Steen
AU - Rasmussen, Torben Riis
AU - Fischer, Barbara Malene
N1 - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.
AB - Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.
UR - https://www.sciencedirect.com/science/article/pii/S1525730419303195
U2 - 10.1016/j.cllc.2019.11.002
DO - 10.1016/j.cllc.2019.11.002
M3 - Journal article
C2 - 31839533
SN - 1525-7304
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
ER -